Dermatomyositis Market Report

Market Overview: 

The 7 major dermatomyositis markets reached a value of US$ 192.9 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 278.0 Million by 2034, exhibiting a growth rate (CAGR) of 3.38% during 2024-2034.

The dermatomyositis market has been comprehensively analyzed in IMARC's new report titled "Dermatomyositis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Dermatomyositis is a rare autoimmune disease that primarily affects the muscles and skin. The symptoms typically include muscle weakness and pain, especially in the proximal muscles of the arms and legs. Patients may also experience a rash, which commonly appears on the face, eyelids, knuckles, etc., and is often accompanied by redness as well as swelling. In addition to this, individuals suffering from dermatomyositis may have difficulty swallowing, as the muscles involved in this process can be affected. Various systemic symptoms, such as fatigue, fever, weight loss, etc., may also be present. Diagnosing the ailment typically involves a combination of medical history evaluation, physical examination, laboratory tests, and sometimes imaging studies. Blood tests are commonly performed to detect certain antibodies, including anti-nuclear antibodies (ANA), anti-Jo-1 antibodies, specific muscle enzymes like creatine kinase (CK), etc., that are often elevated in dermatomyositis. Additionally, an electromyography (EMG) may be conducted to evaluate the electrical activity in the muscles, and a muscle biopsy may be utilized to examine muscle tissue under a microscope for characteristic changes indicative of the disease.

The increasing cases of autoimmune dysfunction, in which the immune system targets blood vessels and muscle tissue, thereby leading to inflammation and damage, are primarily driving the dermatomyositis market. In addition to this, the widespread adoption of biologic agents, such as rituximab or tocilizumab, that work by blocking specific immune pathways involved in inflammation is also creating a positive outlook for the market. Moreover, the escalating utilization of high-dose intravenous immunoglobulin (IVIG) regimens for reducing disease activity, including muscle weakness and systemic symptoms, is further bolstering the market growth. Apart from this, the inflating application of narrowband ultraviolet B (NB-UVB) therapy, which involves the use of a specific wavelength of ultraviolet B light to treat the ailment, is acting as another significant growth-inducing factor. UVB light helps in managing the skin manifestations of dermatomyositis, including the characteristic rash and photosensitivity. Additionally, the emerging popularity of biopsy findings, such as perifascicular atrophy and inflammatory infiltrates, since they aid in differentiating the ailment from other muscle disorders and offer prognostic indicators, is expected to drive the dermatomyositis market during the forecast period. 

IMARC Group's new report provides an exhaustive analysis of the dermatomyositis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for dermatomyositis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the dermatomyositis market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the dermatomyositis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the dermatomyositis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current dermatomyositis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the dermatomyositis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the dermatomyositis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the dermatomyositis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of dermatomyositis across the seven major markets?
• What is the number of prevalent cases (2018-2034) of dermatomyositis by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of dermatomyositis by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with dermatomyositis across the seven major markets?
• What is the size of the dermatomyositis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of dermatomyositis?
• What will be the growth rate of patients across the seven major markets?
   

Dermatomyositis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for dermatomyositis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the dermatomyositis market?
• What are the key regulatory events related to the dermatomyositis market?
• What is the structure of clinical trial landscape by status related to the dermatomyositis market?
• What is the structure of clinical trial landscape by phase related to the dermatomyositis market?
• What is the structure of clinical trial landscape by route of administration related to the dermatomyositis market?